Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline - PubMed
3 hours ago
- #dyslipidemia
- #guideline
- #primary prevention
- Early evaluation for dyslipidemia and genetic forms should start in childhood, with screenings every 5 years after age 19.
- Lifetime screening for lipoprotein(a) (Lp(a)) and selective use of apolipoprotein B (ApoB) testing are recommended for adults.
- Risk assessment uses the PREVENT-ASCVD score to estimate 10-year and 30-year (for ages 30-59) atherosclerotic cardiovascular disease (ASCVD) risk.
- Shared decision-making for lipid-lowering therapy (LLT) initiation considers demographic, clinical, and laboratory data, plus coronary calcium scoring.
- Primary lipid-lowering therapy for primary prevention focuses on statins.
- Treatment goals for LDL-C, non-HDL-C, and apo B are reintroduced based on risk category in primary prevention.
- Guideline updates reflect evolving data to optimize ASCVD risk management.
- The 2026 ACC/AHA multisociety guideline emphasizes primary prevention and screening strategies.
- Risk assessment incorporates multiple factors beyond traditional scores for personalized treatment approaches.
- Management includes evaluating potential genetic dyslipidemias to inform early intervention.